Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Novavax, Inc.

Market Cap 1.46B 1.26B 1.16B 1.09B 2.04B 139B 2.07B 13.72B 5.35B 67.56B 5.48B 5.36B 234B P/E Ratio 2026 *
-18.8x
P/E Ratio 2027 * -34.9x
Enterprise Value 1.68B 1.45B 1.34B 1.25B 2.34B 160B 2.38B 15.78B 6.15B 77.69B 6.3B 6.17B 269B EV / Sales 2026 *
4.1x
EV / Sales 2027 * 6.82x
Free-Float
93.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.66%
1 week-6.43%
Current month-19.05%
1 month-3.79%
3 months-13.24%
6 months+35.16%
Current year+32.14%
1 week 8.35
Extreme 8.35
9.69
1 month 8.35
Extreme 8.35
11.61
Current year 6.76
Extreme 6.76
11.97
1 year 6.13
Extreme 6.13
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Operating Officer - 2020-11-30
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
04-24Fiscal year

Director

19,040 0.0117%
04-13Other

Chief Technology Officer

190,612 0.1170%
04-13Free

Chief Technology Officer

165,500 0.1016%
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%-6.43%+27.95%+10.45% 1.46B
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.54%+0.66%+54.31%+80.43% 21.39B
Weighted average by Cap. +1.03%+1.43%+57.09%+95.46%

Financials

2026 *2027 *
Net sales 410M 354M 326M 305M 572M 38.97B 581M 3.85B 1.5B 18.97B 1.54B 1.51B 65.67B 258M 223M 206M 193M 361M 24.57B 366M 2.43B 947M 11.96B 970M 949M 41.4B
Net income -79.31M -68.5M -63.12M -59.08M -111M -7.54B -112M -745M -291M -3.67B -298M -291M -12.7B -43.22M -37.33M -34.4M -32.2M -60.35M -4.11B -61.28M -406M -158M -2B -162M -159M -6.92B
Net Debt 219M 189M 174M 163M 306M 20.82B 310M 2.06B 802M 10.13B 822M 804M 35.08B 303M 262M 241M 226M 423M 28.82B 430M 2.85B 1.11B 14.03B 1.14B 1.11B 48.57B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-06-12 8.880 $ -1.66% 2,592,147
26-06-11 9.030 $ +5.49% 3,573,358
26-06-10 8.560 $ -1.27% 3,098,776
26-06-09 8.670 $ +0.58% 4,589,829
26-06-08 8.620 $ -9.17% 6,864,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
8.880USD
Average target price
14.11USD
Spread / Average Target
+58.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!